Podcasts about Werewolf

russian bush werewolf cannibal russian soldiers

Play Episode Listen Later Jun 28, 2025 84:05

Before 2017, tonight's guest, Dave, had spent countless hours in the woods and around them. Due to all the he'd spent in them, he was convinced that he knew about everything and anything he could expect to encounter. One evening, however, he came to realize just how wrong he was about that. Before 2017, Dave would have believed in the existence of a lot of things, but Dogmen weren't on the list. That night, in 2017, when he had his first encounter with one, he realized that they should be on it. We hope you listen to Dave walk you through what happened that night and share other experiences he's had.MY NEW DOGMAN PODCAST!Tonight, at 9 PM Eastern Time, I'm going to publish 4 more new episodes for my new Dogman podcast. My new podcast is called "Dogman Tales.” It features fictional stories about Dogmen and people who have experiences with them. The podcast is only available for listening in podcast format. It is NOT available on YouTube. If you'd like to listen to it, you can find the show wherever you listen to podcasts. Dogman Tales is available for listening on every podcast app out there. If you don't have a go-to podcast app, here's a link to the Dogman Tales Podcast Page, on Spreaker...https://www.spreaker.com/podcast/dogman-tales--6640134Premium memberships are now available! If you'd like to listen to the show without ads and have full access to premium content, please go to https://DogmanEncounters.com/Podcast to learn how to become a premium member.If you've had a Dogman encounter and need help or would like to be a guest on the show, please go to https://DogmanEncounters.com and submit a report. I'd love to hear from you.If you'd like to help support the show, by buying your own Dogman Encounters t-shirt, sweatshirt, tank top, or coffee mug, please visit the Dogman Encounters Show Store, by going to https://Dogman-Encounters.MyShopify.comIf you've had a Sasquatch sighting and would like to be a guest on My Bigfoot Sighting, please go to https://MyBigfootSighting.com and submit a report.I produce 4 other shows that are available on your favorite podcast app. If you haven't checked them out, here are links to all 4 channels on the Spreaker App...Dogman Tales... https://www.spreaker.com/podcast/dogman-tales--6640134My Bigfoot Sighting... https://spreaker.page.link/xT7zh6zWsnCDaoVa7 Bigfoot Eyewitness Radio... https://spreaker.page.link/WbtSccQm92TKBskT8 My Paranormal Experience https://www.spreaker.com/show/my-paranormal-experience Thanks for listening!

horror monster terror scary monsters nightmare scared creatures werewolf sasquatch spreaker cryptids werewolves comif dogman frightening terrifying dogmen lucan nightmarish lycans dogman encounters spreaker app myshopify dogman encounters show store

Ep. 214 - Cannibal Russian Soldiers & a Werewolf President

CAMP STRANGE

Play Episode Listen Later Jun 27, 2025 116:38

Send us a textHey campers, get away from that secret society and over to the fire, we got some stories to tell. This week we tell you about Dennis Gorin, the murderous cannibal criminal who got upgraded to soldier in the Russian military because why not?! We also tell you about the Bush family and their secret ties to secret societies that turned them into secret werewolves.....shhh it's a secret.

"The Werewolf Next Door" - A horror story - by S.J. Walker

Tall Tale TV

Play Episode Listen Later Jun 27, 2025 21:05

The Werewolf Next Door ep.782 S.J. Walker has published many short stories in dark fantasy, including 7 with Dragon Soul Press so far, among others. She has also sold stories to podcasts including Thirteen Podcast, Creepy Podcast, No Sleep, Flash Fiction Podcast, etc. She's currently working on her debut novel. More TTTV Stories by S.J. Walker https://talltaletv.com/tag/s-j-walker/ ---- Listen Elsewhere ---- YouTube: https://www.youtube.com/c/TallTaleTV Website: http://www.TallTaleTV.com ---- Story Submission ---- Got a short story you'd like to submit? Submission guidelines can be found at http://www.TallTaleTV.com ---- About Tall Tale TV ---- Hi there! My name is Chris Herron and I'm an audiobook narrator. In 2015, I suffered from poor Type 1 diabetes control which lead me to become legally blind for almost a year. The doctors didn't give me much hope, predicting an 80% chance that I would never see again. But I refused to give up and changed my lifestyle drastically. Through sheer willpower (and an amazing eye surgeon) I beat the odds and regained my vision. During that difficult time, I couldn't read or write, which was devastating as they had always been a source of comfort for me since childhood. However, my wife took me to the local library where she read out the titles of audiobooks to me. I selected some of my favorite books, such as the Disc World series, Name of the Wind, Harry Potter, and more, and the audiobooks brought these stories to life in a way I had never experienced before. They helped me through the darkest period of my life and I fell in love with audiobooks. Once I regained my vision, I decided to pursue a career as an audiobook narrator instead of a writer. That's why I created Tall Tale TV, to support aspiring authors in the writing communities that I had grown to love before my ordeal. My goal was to help them promote their work by providing a promotional audio short story that showcases their writing skills to readers. They say the strongest form of advertising is word of mouth, so I offer a platform for readers to share these videos and help spread the word about these talented writers. Please consider sharing these stories with your friends and family to support these amazing authors. Thank you! ---- legal ---- All stories on Tall Tale TV have been submitted in accordance with the terms of service provided on http://www.talltaletv.com or obtained with permission by the author. All images used on Tall Tale TV are either original or Royalty and Attribution free. Most stock images used are provided by http://www.pixabay.com , https://www.canstockphoto.com/ or created using AI. Image attribution will be declared only when required by the copyright owner. Common Affiliates are: Amazon, Smashwords

amazon ai harry potter wind submission werewolf horror stories nextdoor attribution no sleep discworld smashwords chris herron talltaletv

His Friends Think He's A Werewolf

OFF THE COURSE - AN AMERICAN NINJA WARRIOR PODCAST

Play Episode Listen Later Jun 27, 2025 1:04

friends werewolf

Immunotherapy at ASCO25: Drug Development, Melanoma Treatment, and More

ASCO Daily News

Play Episode Listen Later Jun 27, 2025 27:01

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode. Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency. So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated. Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations. And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Diwakar Davar   @diwakardavar   Dr. Jason Luke @jasonlukemd Follow ASCO on social media:    @ASCO on Twitter      ASCO on Bluesky  ASCO on Facebook      ASCO on LinkedIn Disclosures:    Dr. Diwakar Davar:     Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences    Consulting or Advisory Role: Instil Bio, Vedanta Biosciences    Consulting or Advisory Role (Immediate family member): Shionogi    Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences    Research Funding (Inst.): Zucero Therapeutics    Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy    Dr. Jason Luke:    Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX    Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine    Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure    Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)    Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

university ai spring patients stage pittsburgh treatments phase fda iv pfizer supreme keynote gi werewolf relation cart mrna pd bayer immune abstract mg oncology merck endeavor caucasians janssen checkmate soc novartis melanoma relativity royalties lag accommodations cancer care immunotherapy gsk asco genentech orr abbvie bristol myers squibb stipe takeda drug development regeneron hla gilead sciences adverse events mek nektar rfs us fda lnp onc european medicines agency prognostic cancer immunotherapy braf eisai cd3 tils asco annual meeting pyxis iiib iic iib servier rubius cd8 t ctla ctdna rp1 incyte emd serono alnylam iiia genmab moderna therapeutics 76k braf v600e eortc ajcc tigit tesaro jason luke transcript dr array biopharma synlogic gp100

Episode 329: 'Kracker Jack'd' (2003)/ 'Unnatural' (2024)

Adventures in Movies!

Play Episode Listen Later Jun 27, 2025 63:32

We were so excited to see 28 Years Later and based off of the box office, we were not the only ones. And much like many of those who went to see it, we have mixed opinions on it (most of it not good.) We are a little surprised that there is another adaptation of Stephen King's The Stand. We understand that there will always be retellings of King's works - and retellings of those retellings.But this one caught us off guard since it is so soon since the recent miniseries based on his book. Even stranger is how it will reportedly all be done in one movie. It sounds like a recipe for disaster, but it is in good hands. Much like Weapons, whose marketing continues to impress.It is strange how the silliest things will make you think of the most serious issues. Kracker Jack'd (or CrackerJack: The Movie) is an inconsequential comedy horror movie from the early 2000s that somehow got us really worked up. This shouldn't be a surprise being that it is written and directed by a white man who calls himself an “honorary soul brother”. Putting the racial insensitivity aside - which is pretty much impossible since it uses stereotypes that range from modern Black life to ugly myths created during slavery - it just isn't a very good movie. Along with being tone deaf , it is poorly edited and nonsensical. There is a good joke to be found, but this is a bad movie. On the plus side, it provides the best line ever heard on this show.It is a low bar when it comes to the best performance by a wrestler. Pro wrestlers usually play themselves. And when they are given a character a part, it is basically the same thing. Sure there are exceptions like Roddy Piper and Bautista, but the norm is Hulk Hogan and The Rock. Al Snow may not be the biggest name in pro grapes, but his performance in 2024's Unnatural is one of the best we have ever seen from a wrestler.It is too bad that the rest of the movie could not keep up with him. It is way too long. You could have shaved close to an hour off of this and gotten a much better film. The dialogue is also really bad. But the Snowman succeeds in making it watchable. He has great screen presence, is funny, and is the only consistent character. We definitely want to see more of him in the future. Adventures in Movies! is a part of the Morbidly Beautiful Podcast Network. Morbidly Beautiful is your one stop shop for all your horror needs. From the latest news and reviews to interviews and old favorites, it can be found at Morbidly Beautiful.Adventures in Movies! is hosted by Nathaniel and Blake. You can find Nathaniel on Instagram at nathaninpoortaste. Blake can be found on Twitter @foureyedhorror and on Instagram at foureyedhorror. You can reach us personally or on Twitter @AdventuresinMo1.Music in the background from https://www.FesliyanStudios.com

music black movies rock stand putting adventures zombies vampires weapons stephen king adaptation werewolf hulk hogan trailers snowman tubi bautista unnatural roddy piper al snow black horror fesliyanstudios western horror kracker morbidly beautiful podcast network

PNFM - EP132 - O Mistério da Dália Negra

Paranormal FM

Play Episode Listen Later Jun 27, 2025 43:26

No episódio de hoje, Ribas e Leo trazem o misterioso caso do assassinato de Elizabeth Short, também conhecido como "O caso da Dália Negra". Não recomendado para menores de 18 anos.=== ACESSE NOSSO CANAL NO YOUTUBE ===https://www.youtube.com/@paranormalfm=== LOJA DE CAMISAS OFICIAS PNFM ===https://reserva.ink/paranormalfm=== APOIE O PARANORMAL FM ===Quer se tornar um apoiador deste projeto e nos ajudar a continuar melhorando a qualidade, além e se tornar uma peça importante na viabilização muitos outros projetos em diferentes mídias? Entre no nosso Apoia-se e faça parte da família Paranormal FM!https://apoia.se/paranormalfm=== Siga Paranormal FM nas redes sociais ===Instagram, Twitter e Facebook: @ParanormalFMEmail: paranormalfmpodcast@gmail.comSiga e avalie o Paranormal FM nas plataformas de streaming!Apresentação: Fernando Ribas e Leonardo MarquesVinhetas e Formato: Fernando RibasEdição: Athelas Soluções em ÁudioPauta: Luana MachadoSee omnystudio.com/listener for privacy information.

Episode 802 Experiences; A Werewolf On the Road, An Unexpected Voice, and More

SalsidoParanormal Podcast

Play Episode Listen Later Jun 26, 2025 24:08

#paranormal #supernatural A possible werewolf sighting, a disembodied voice, and more True Paranormal Stories From the Web. Please follow Jen, the Arcane Observer, who is now the official co-host of Salsido Paranormal; https://linktr.ee/jenniferhawkins_arcana Have you ever had an experience with the paranormal, supernatural, and / or unexplained, that you would like others to know about? If so, let me know. You can reach me at; salsidoparanormal@gmail.com Follow Mike, host of Troubled Minds Radio. https://www.troubledminds.org/ You can now listen to 2 episodes of the show every night at 6 pm Pacific / 9 pm Eastern on the Troubled Minds Radio Network KUAP-DB! https://www.troubledminds.org/ Also, if you or anyone you know should ever feel like there is no hope, or help, please consider the information in the link below. Special thanks to Michael Strange for putting this page together. https://www.troubledminds.net/help You can find all episodes, social media, and ways to support the show via the links below. https://www.salsidoparanormal.com/ https://www.bonfire.com/store/salsido-paranormal/

voice experiences web unexpected pacific werewolf

EP 240 - Hail Seitan -

Och Menno

Play Episode Listen Later Jun 25, 2025 23:21

Moin, ja die Folge hat sich gegessen .. etwas über merkwürdige Diäten in der Vergangenheit damit ihr euch nicht schlecht fühlt wenn ihr den neusten Trend nicht mitmacht. Musik: Hail Seitan https://www.youtube.com/watch?v=eovuIfeH2k4 Links: https://www.focus.de/kultur/leben/vegane-bloggerin-zhanna-samsonova-stirbt-wegen-extremer-diaet_id_200633974.html https://en.wikipedia.org/wiki/Salisbury_steak https://en.wikipedia.org/wiki/James_H._Salisbury https://en.wikipedia.org/wiki/Kellogg%27s https://en.wikipedia.org/wiki/John_Harvey_Kellogg https://en.wikipedia.org/wiki/Will_Keith_Kellogg https://en.wikipedia.org/wiki/Fad_diet https://en.wikipedia.org/wiki/List_of_diets#Fad_diets https://en.wikipedia.org/wiki/Inedia https://en.wikipedia.org/wiki/Ann_Louise_Gittleman#Books https://en.wikipedia.org/wiki/Werewolf_diet https://en.wikipedia.org/wiki/Morning_banana_diet https://en.wikipedia.org/wiki/Aseem_Malhotra#Pioppi_diet_and_low_carb_diet_advocacy https://en.wikipedia.org/wiki/Lamb_chop_and_pineapple_diet https://en.wikipedia.org/wiki/Dave_Asprey

lamb trend vergangenheit hail werewolf kellogg salisbury moin dave asprey fad seitan

E|139 The werewolf Butcher REDUX: Part Two

Play Episode Listen Later Jun 24, 2025 40:45

The week we revisit one of our most disturbing cases ever... The Werewolf Butcher. Jack Spillman had one goal: to be the greatest serial killer of all time. Would he succeed? Learn more about your ad choices. Visit podcastchoices.com/adchoices

butcher werewolf redux

E|139 The Werewolf Butcher REDUX: Part Two (Bonus)

butcher werewolf redux branden

Play Episode Listen Later Jun 24, 2025 27:24

Carolyn and Branden discuss the episode. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Werewolf the Podcast: The Werewolf Sacrifices Himself (Episode 214)

Werewolf the Podcast

Play Episode Listen Later Jun 24, 2025 28:36

Send us a textWilliam Marshall has decided to stop the continuing fighting and siege by giving himself to the new Count de Perigord (Direct descendant of Charlemagne). He wanders his weary way to the camp to be met by the brave cock and his mercenary soldiers. Gervais de Montagne prays for an angel to come to help. He gets an angel but not one he expects.This is this week's exciting episode of Werewolf the Podcast: A Serial (Killer) Drama.Go check out Odin Apparel for amazing Viking-themed kits and our t-shirts. Preorder it now at this link.https://odinapparel24.myshopify.com/collections/werewolf-a-serial-killer-podcastThe Old Man's Podcast:The writing duo speak to the Old Man himself. Go check us out on his award-winning Podcast.https://podcasts.apple.com/gb/podcast/the-old-mans-podcast/id1595940192?i=1000708626677Grendel Press, our horror genre partnerhttps://grendelpress.com/Grendel's very own cool Podcast.https://grendelpress.com/sinister-soup. Buy us a coffee at this link right here:https://www.buymeacoffee.com/WerewolfwilBuy a book about werewolves. Here it is, straight from a fang-filled mouth.Il LupoGreg's first Werewolf book. Brilliantly written characters in an incredible story. https://books2read.com/ILLUPOA Werewolf's Storyhttps://amzn.to/3BjXoZuWerewolf the Colouring Book.What should I do this evening? Why not sit and do some Wonderful Werewolf colouring? Red may be a theme.https://amzn.to/40k93l6Facebook Grouphttps://www.facebook.com/groups/werewolfthepodcast/Greg's X profile:@SempaiGregWerewolf the Podcast:@AWerewolfsStoryWilIntro partnership with Grendel Press.https://grendelpress.com/ Outro partnership with Grendel Press.https://grendelpress.com/Support the show

viking old man werewolf sacrifices montagne charlemagne gervais grendel

Bride of Monster Kid Radio #031 - Frankenstein Meets the Wolfman meets David Heath

Monster Kid Radio

Play Episode Listen Later Jun 23, 2025 90:50

David Heath joins Derek and Beth to tackle a bona fide classic - Frankenstein Meets the Wolfman (dir. Roy William Neill). Plus Mark Matzke's Beta Capsule Review (Ultraman Ace), and Kenny's Look at Famous Monsters of Filmland! Voicemail: (360) 524-2484‬ Email: Monster Kid Radio's Discord Server - Monster Kid Radio on Reddit - Monster Kid Radio on Twitch! - Monster Kid Radio on YouTube - Follow Mark MatzkeSmall Town Monsters - Follow David Heath People's Guide to the Cthulhu Mythos - Wasabi Con PDX - Ray Harryhausen: Miniature Models of the Silver Screen - Deth Designs - Classic Horror Film Board - Executive Producer: "" () provided courtesy of Bride of Monster Kid Radio is a Production. All original content of Bride of Monster Kid Radio is licensed under a . You can learn more about Team Deth, our other projects like Deth Merchant, Mail Order Zombie, Deth Writer, and more at . Please rate and review Monster Kid Radio wherever you download your favorite podcasts. Next week on Bride of Monster Kid Radio: STAY TUNED!

guide twitch production universal werewolf voicemail wolfman classic horror lycanthropy famous monsters filmland lycanthrope frankenstein meets david heath monster kid radio roy william neill

Ways of the Wyrd #1 - Historical Werewolf Accounts

Monsters, Madness and Magic

Play Episode Listen Later Jun 23, 2025 30:05

In this first entry of Ways of the Wyrd, join Justin as he details historical accounts of Werewolfery in Eastern and Western Europe, citing sources from occult scholar and theologian Montague Summers.Montague Summers bio:“Augustus Montague Summers (10 April 1880 – 10 August 1948) was an English author, clergyman, and teacher. As an independent scholar, he published many works on the English drama of the Stuart Restoration (1660–1688) and helped to organise and to promote the performance of plays from that period. He also wrote extensively on the occult and has been characterized as "arguably the most seminal twentieth century purveyor of pop culture occultism.”Intro and outro theme created by Wyrm. Support Wyrm by visiting the Serpents Sword Records bandcamp page (linked below):https://serpentsswordrecords.bandcamp.com/Monsters, Madness and Magic Official Website. Monsters, Madness and Magic on Linktree.Monsters, Madness and Magic on Instagram.Monsters, Madness and Magic on Facebook.Monsters, Madness and Magic on Twitter.

english magic madness monsters historical accounts linktree werewolf western europe wyrd wyrm montague summers

CURSE ON CAPE HOWE: A Werewolf On The Island – Where Can You Run?

Weird Darkness: Stories of the Paranormal, Supernatural, Legends, Lore, Mysterious, Macabre, Unsolved

Play Episode Listen Later Jun 21, 2025 290:02

Tonight on Dark Fantasy… the moon rises ,and a child of man becomes a creature of the NIGHT! Don't miss… ‘W Is For Werewolf: A Tale of Lycanthropic Terror!' | #RetroRadio EP0442Join the DARKNESS SYNDICATE: https://weirddarkness.com/syndicateCHAPTERS & TIME STAMPS (All Times Approximate)…00:00:00.000 = Show Open00:01:50.000 = CBS Radio Mystery Theater, “The Cornstarch Killer” (May 03, 1976) ***WD00:47:34.419 = Dark Fantasy, “W Is For Werewolf” (February 13, 1942)01:12:01.538 = Diary of Fate, “Marvin Thomas Entry” (June 08, 1948) ***WD01:41:18.398 = BBC Fear on 4, “Dreaming of Thee” (February 12, 1989)02:08:16.851 = Five After the Hour, “Song of the River” (June 06, 1945)02:32:33.280 = Five Minute Mysteries, “Return of Mr. Lawrence” (late 1940s)02:37:42.689 = Tales From The Tomb, “The Girl of His Dreams” (1960s)02:41:27.288 = Future Tense, “Protection” (May 29, 1974) ***WD (LQ)03:04:53.662 = Gang Busters, “John Frederick Benson” (February 28, 1948)03:27:43.884 = The Green Hornet, “Ripe For The Taking” (September 05, 1939)03:57:06.653 = The Lives of Harry Lime, “Pearls of Bohemia” (May 30, 1952) ***WD04:22:09.631 = BBC Haunted Tales of the Supernatural, “Which One” (January 14, 1980)04:48:52.458 = Show Close(ADU) = Air Date Unknown(LQ) = Low Quality***WD = Remastered, edited, or cleaned up by Weird Darkness to make the episode more listenable. Audio may not be pristine, but it will be better than the original file which may have been unusable or more difficult to hear without editing.Weird Darkness theme by Alibi Music LibraryABOUT WEIRD DARKNESS: Weird Darkness is a true crime and paranormal podcast narrated by professional award-winning voice actor, Darren Marlar. Seven days per week, Weird Darkness focuses on all thing strange and macabre such as haunted locations, unsolved mysteries, true ghost stories, supernatural manifestations, urban legends, unsolved or cold case murders, conspiracy theories, and more. On Thursdays, this scary stories podcast features horror fiction along with the occasional creepypasta. Weird Darkness has been named one of the “Best 20 Storytellers in Podcasting” by Podcast Business Journal. Listeners have described the show as a cross between “Coast to Coast” with Art Bell, “The Twilight Zone” with Rod Serling, “Unsolved Mysteries” with Robert Stack, and “In Search Of” with Leonard Nimoy.= = = = ="I have come into the world as a light, so that no one who believes in me should stay in darkness." — John 12:46= = = = =WeirdDarkness® is a registered trademark. Copyright ©2025, Weird Darkness.= = = = =CUSTOM WEBPAGE: https://weirddarkness.com/WDRR0442

Please! Don't Come In! - Dogman Encounters Episode 587

Play Episode Listen Later Jun 21, 2025 61:07

Almost one year ago, to the day, tonight's guest had an encounter that she's, just now, coming to terms with. You see, when she had her first encounter, she saw the Dogman. It was less than 30 feet from her when she laid eyes on it. Needless to say, she didn't waste any time getting away from it. What happened moments later, after she thought the two of them had gone their separate ways, however, was more traumatizing to her than when she had seen it at such a close distance, moments before. We hope you'll join us for tonight's livestream episode of the show, so you can listen to her describe what happened when she had both encounters. If you do, you'll understand why they traumatized her the way they did.MY NEW DOGMAN PODCAST!Tonight, at 9 PM Eastern Time, I'm going to publish 4 more new episodes for my new Dogman podcast. My new podcast is called "Dogman Tales.” It features fictional stories about Dogmen and people who have experiences with them. The podcast is only available for listening in podcast format. It is NOT available on YouTube.If you'd like to listen to it, you can find the show wherever you listen to podcasts. Dogman Tales is available for listening on every podcast app out there. If you don't have a go-to podcast app, here's a link to the Dogman Tales Podcast Page, on Spreaker...https://www.spreaker.com/podcast/dogman-tales--6640134Premium memberships are now available! If you'd like to listen to the show without ads and have full access to premium content, please go to https://DogmanEncounters.com/Podcast to learn how to become a premium member.If you've had a Dogman encounter and need help or would like to be a guest on the show, please go to https://DogmanEncounters.com and submit a report. I'd love to hear from you.If you'd like to help support the show, by buying your own Dogman Encounters t-shirt, sweatshirt, tank top, or coffee mug, please visit the Dogman Encounters Show Store, by going to https://Dogman-Encounters.MyShopify.comIf you've had a Sasquatch sighting and would like to be a guest on My Bigfoot Sighting, please go to https://MyBigfootSighting.com and submit a report.I produce 4 other shows that are available on your favorite podcast app. If you haven't checked them out, here are links to all 4 channels on the Spreaker App...Dogman Tales... https://www.spreaker.com/podcast/dogman-tales--6640134My Bigfoot Sighting... https://spreaker.page.link/xT7zh6zWsnCDaoVa7 Bigfoot Eyewitness Radio... https://spreaker.page.link/WbtSccQm92TKBskT8 My Paranormal Experience https://www.spreaker.com/show/my-paranormal-experience Thanks for listening!

horror monster terror scary monsters nightmare scared creatures needless werewolf sasquatch spreaker cryptids werewolves comif dogman frightening terrifying dogmen lucan nightmarish lycans dogman encounters spreaker app myshopify dogman encounters show store

Women InSession: Favorite Werewolf Movies

InSession Film Podcast

Play Episode Listen Later Jun 21, 2025 62:37

This week on Women InSession, after discussing vampires and witches in recent weeks, we thought it would be fun to continue the trend by discussing our favorite werewolf movies! Panel: Kristin Battestella, Jaylan Salah Shop merch here: https://insessionfilm.com/store/ Thanks for listening and be sure to subscribe on your podcast app of choice! https://insessionfilm.com/subscribe

women movies werewolf

Archive 173 Texas Bigfoot

horror zombies ufos vampires bigfoot paranormal audiobooks archive werewolf yeti sasquatch dogman texas bigfoot

Play Episode Listen Later Jun 20, 2025 25:58

Archive 173 Texas BigfootJoin my Supporters Club for $4.99 per month for exclusive stories:https://www.spreaker.com/podcast/what-if-it-s-true-podcast--5445587/support

PNFM - EP131 - As Previsões dos Simpsons - Parte 02

Paranormal FM

Play Episode Listen Later Jun 20, 2025 56:40

No episódio de hoje, Ribas e Leo vão dar um "rolêzinho" em Springfield para conferir as famosas profecias dos Simpsons! Este episódio é parte 2 de 2.=== ACESSE NOSSO CANAL NO YOUTUBE ===https://www.youtube.com/@paranormalfm=== LOJA DE CAMISAS OFICIAS PNFM ===https://reserva.ink/paranormalfm=== APOIE O PARANORMAL FM ===Quer se tornar um apoiador deste projeto e nos ajudar a continuar melhorando a qualidade, além e se tornar uma peça importante na viabilização muitos outros projetos em diferentes mídias? Entre no nosso Apoia-se e faça parte da família Paranormal FM!https://apoia.se/paranormalfm=== Siga Paranormal FM nas redes sociais ===Instagram, Twitter e Facebook: @ParanormalFMEmail: paranormalfmpodcast@gmail.comSiga e avalie o Paranormal FM nas plataformas de streaming!Apresentação: Fernando Ribas e Leonardo MarquesVinhetas e Formato: Fernando RibasEdição: Athelas Soluções em ÁudioPauta: Luana MachadoSee omnystudio.com/listener for privacy information.

EPISODE 125: OPERATION BLOOD HUNT (2024)

Ear For Fear

Play Episode Listen Later Jun 19, 2025 35:31

Operation Blood Hunt. Join Rick and Danny as they talk about this 2024 werewolf flick. Is this b-horror effort interesting enough to Bark at the Moon, or does Operation lack bite and in desperate need of a blood fusion?

death blood moon military vampires hunt survival operation werewolf werewolves bark south pacific low budget b horror

Man Thinks His Friend's A Werewolf, Tries To Stab Him With A Wooden Stake

Doc's Dumb Dumb of the Day

Play Episode Listen Later Jun 19, 2025 2:10

Jose Perez of Salt Lake City was arrested after lunch with a buddy took an unexpected turn. Jose had gotten it into his head that his friend was a werewolf and felt he needed to take appropriate actions.See omnystudio.com/listener for privacy information.

friend salt lake city werewolf stake wooden stab jose perez

Werewolf Attack (Airdate 6/18/2025)

Bob & Sheri

Play Episode Listen Later Jun 18, 2025 72:21

Mathew Perry. Diddy News. Morons in the News. Small Plates. Everyone Needs a Laugh. Talkback Callers. The Vegas Airport. Can You Believe This? TSA and Those Mini Airplane Booze Bottles. From the Vault.

news attack laugh vault werewolf tsa everyone needs morons small plates

Archive 172 Bigfoot

Holmberg's Morning Sickness

Play Episode Listen Later Jun 18, 2025 31:00

Archive 172 BigfootJoin my Supporters Club for $4.99 per month for exclusive stories:https://www.spreaker.com/podcast/what-if-it-s-true-podcast--5445587/support

horror zombies ufos vampires bigfoot paranormal audiobooks archive werewolf yeti sasquatch dogman buckner

06-18-25 - BR - THU - Study On Trust And Which Countries Are Most Trustworthy And Toledo's Wife Was In No Kings Protest - Man Attacked By Man w/Wooden Stake He Thought Was A Werewolf

Play Episode Listen Later Jun 18, 2025 31:47

06-18-25 - BR - THU - Study On Trust And Which Countries Are Most Trustworthy And Toledo's Wife Was In No Kings Protest - Man Attacked By Man w/Wooden Stake He Thought Was A WerewolfSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

study wife protests countries toledo werewolf stake trustworthy wooden no kings man attacked

06-18-25 - BR - THU - Study On Trust And Which Countries Are Most Trustworthy And Toledo's Wife Was In No Kings Protest - Man Attacked By Man w/Wooden Stake He Thought Was A Werewolf

Holmberg's Morning Sickness - Arizona

Play Episode Listen Later Jun 18, 2025 31:47

study wife protests countries toledo werewolf stake trustworthy wooden no kings man attacked

Bullet Proof Bigfoot

horror zombies ufos vampires bigfoot paranormal audiobooks werewolf yeti sasquatch bulletproof dogman

Play Episode Listen Later Jun 17, 2025 29:17

Bullet Proof BigfootIn Southern Virginia, a 14-year-old and his friend encountered terrifying creatures during outdoor activities. While archery hunting, they spotted what seemed like a bear cub, but it stood upright, snarled, and fled, leaving the friend traumatized. Years later, while fishing and checking trail cameras, the narrator, now 6'7" and 240 pounds, encountered a ten-foot-tall, brownish-blonde, hairy creature. When it charged, he fired #4 buckshot, but the pellets seemed to bounce off. The creature roared as if speaking and retreated into the forest. Both incidents left the narrator and his friend unwilling to return to those areasJoin my Supporters Club for $4.99 per month for exclusive stories:https://www.spreaker.com/podcast/what-if-it-s-true-podcast--5445587/support

E|138 The Werewolf Butcher Redux: Part One

Play Episode Listen Later Jun 17, 2025 47:02

The week we revisit one of our most disturbing cases ever... The Werewolf Butcher. Jack Spillman had one goal: t be the greatest serial killer of all time. Would he succeed? Learn more about your ad choices. Visit podcastchoices.com/adchoices

butcher werewolf redux

E|138 The Werewolf Butcher REDUX: Part One (Bonus)

butcher werewolf redux branden

Play Episode Listen Later Jun 17, 2025 34:10

Carolyn and Branden discuss the episode . Learn more about your ad choices. Visit podcastchoices.com/adchoices

Archive 171 Bigfoot

twitch curse production werewolf voicemail wolfman oliver reed famous monsters filmland terence fisher curse of the werewolf monster kid radio

Play Episode Listen Later Jun 16, 2025 27:39

Archive 171 BigfootJoin my Supporters Club for $4.99 per month for exclusive stories:https://www.spreaker.com/podcast/what-if-it-s-true-podcast--5445587/support

horror zombies ufos vampires bigfoot paranormal audiobooks archive werewolf yeti sasquatch dogman buckner

Bride of Monster Kid Radio #030 - The Curse of the Werewolf with Matt Rashleigh

Monster Kid Radio

Play Episode Listen Later Jun 16, 2025 74:15

Oliver Reed as a werewolf? Really? YES! REALLY! Bride of Monster Kid Radio continues its look at lycanthropic cinema when Matt Rashleigh joins Derek for a look at The Curse of the Werewolf (dir. Terence Fisher). Plus Kenny's Look at Famous Monsters of Filmland! Voicemail: (360) 524-2484‬ Email: Monster Kid Radio's Discord Server - Monster Kid Radio on Reddit - Monster Kid Radio on Twitch! - Monster Kid Radio on YouTube - Ray Harryhausen: Miniature Models of the Silver Screen - Deth Designs - Classic Horror Film Board - Executive Producer: "" () provided courtesy of Bride of Monster Kid Radio is a Production. All original content of Bride of Monster Kid Radio is licensed under a . You can learn more about Team Deth, our other projects like Deth Merchant, Mail Order Zombie, Deth Writer, and more at . Please rate and review Monster Kid Radio wherever you download your favorite podcasts. Next week on Bride of Monster Kid Radio: STAY TUNED!

Episode 929 - The Werewolf Movies of 1981

Dread Media

Play Episode Listen Later Jun 16, 2025 124:06

This week, our old pal Greg Lamberson is back, and in honor of his upcoming film, Frenzy Moon, we review the four werewolf films from 1981: The Howling, Wolfen, An American Werewolf in London, and Full Moon High. That's three Mount Rushmore werewolf movies and I don't know what the hell Full Moon High is. Some howling tunes: "Frenzy" by Killing Joke, "The Howling" by Bloody Hammers, "Wolfen" by Mortician, "American Werewolves in London" by Wednesday 13, "On a Night of Full Moon" by Mercyful Fate, and "The Killing Moon" by Echo and The Bunnymen. Send feedback to: dreadmediapodcast@gmail.com. Follow @DevilDinosaurJr and @dreadmedia on Twitter! Join the Facebook group! Support the show at www.patreon.com/dreadmedia. Visit www.desmondreddick.com, www.stayscary.wordpress.com, www.dreadmedia.bandcamp.com, www.kccinephile.com, and www.dejasdomicileofdread.blogspot.com.

music movies film night horror fantasy zombies monster geeks comic echo science fiction comic books mount rushmore werewolf full moon frenzy slasher howling american werewolf in london killing joke mortician earth-2 bunnymen mercyful fate wolfen killing moon bloody hammers full moon high earth-2.net greg lamberson american werewolves desmond reddick earth-2.net: the show reel dread

The Bronze Age of Horror Comics! Werewolf by Night extended coverage! Spider-Woman and Ghost Rider!

Magazines and Monsters

Play Episode Listen Later Jun 16, 2025 83:52

Hey everybody, Al Sedano is back and we've got more coverage of the exploits of Jack Russell, Werewolf by Night! We cover three appearances in the pages of Spider-Woman (32), Marvel Premiere (59), and Ghost Rider (55)! These are very interesting but very different stories but two of them do reference continuity. With only three more episodes of coverage after this episode, we'd love for you guys and gals to let us know some of your favorite appearances, whether they be classic or modern! Hit us up on Twitter @AdamThanospod (Al) and @Billyd_licious (me) or through email at Magazinesandmonsters@gmail.com or look us up on BlueSky as well! Thanks for listening.

ghosts night coverage blue sky werewolf ghost rider bronze age spider woman jack russell horror comics marvel premiere al sedano

Bigfoot Looks Like a Human

washington ghosts story storytelling horror zombies ufos vampires bigfoot paranormal audiobooks werewolf yeti sasquatch cryptids spotting dogman buckner

Play Episode Listen Later Jun 15, 2025 32:28

Bigfoot Looks HumanA Native American woman, accustomed to solitary wilderness adventures, recounts a vivid encounter from nearly 20 years ago at a crowded beach in northeastern Washington. While kayaking with family, she lingered alone offshore to eat lunch and felt uneasy. Spotting a tall, handsome man with silver-tipped body hair watching her intently from the shore, she initially mistook him for an elderly human. As she paddled closer, she realized he was not elderly but a striking, eight-foot-tall being, naked and covered in glossy hair, exuding intelligence and a human-like presence. Despite his non-threatening demeanor, he vanished into the trees, and she later noticed a figure tracking her from a distant mountain. After sharing her story online, she faced ridicule but connected with others through Bigfoot forums, insisting the being was a man, not an animal, and seeking others with similar experiences.Join my Supporters Club for $4.99 per month for exclusive stories:https://www.spreaker.com/podcast/what-if-it-s-true-podcast--5445587/support

Archive 170 Zombies

ghosts storytelling horror zombies ufos vampires bigfoot paranormal audiobooks archive werewolf yeti sasquatch cryptids dogman buckner lycanthrope

Play Episode Listen Later Jun 14, 2025 25:26

Archive 170 ZombiesJoin my Supporters Club for $4.99 per month for exclusive stories:https://www.spreaker.com/podcast/what-if-it-s-true-podcast--5445587/support

Let's Talk About Your Booger Bear Encounters - Dogman Encounters Episode 586

Play Episode Listen Later Jun 14, 2025 61:49

Tonight's guest, “Phoenix,” came on last week's livestream and shared some of the Dogman-related experiences he's had, including the night when he was tormented by one when he was home alone, when he was only 12 years old (he and his family call them “Booger Bears”). Tonight, he'll be back to share more encounters he's had with you and to answer the questions I have for him, about his experiences. If you're in the live chat and have questions for him, he'll be ready to answer your questions too. We hope you'll join us!MY NEW DOGMAN PODCAST!Tonight, at 9 PM Eastern Time, I'm going to publish 4 more new episodes for my new Dogman podcast. My new podcast is called "Dogman Tales.” It features fictional stories about Dogmen and people who have experiences with them. The podcast is only available for listening in podcast format. It is NOT available on YouTube. If you'd like to listen to it, you can find the show wherever you listen to podcasts. Dogman Tales is available for listening on every podcast app out there. If you don't have a go-to podcast app, here's a link to the Dogman Tales Podcast Page, on Spreaker...https://www.spreaker.com/podcast/dogman-tales--6640134Premium memberships are now available! If you'd like to listen to the show without ads and have full access to premium content, please go to https://DogmanEncounters.com/Podcast to learn how to become a premium member.If you've had a Dogman encounter and need help or would like to be a guest on the show, please go to https://DogmanEncounters.com and submit a report. I'd love to hear from you.If you'd like to help support the show, by buying your own Dogman Encounters t-shirt, sweatshirt, tank top, or coffee mug, please visit the Dogman Encounters Show Store, by going to https://Dogman-Encounters.MyShopify.comIf you've had a Sasquatch sighting and would like to be a guest on My Bigfoot Sighting, please go to https://MyBigfootSighting.com and submit a report.I produce 4 other shows that are available on your favorite podcast app. If you haven't checked them out, here are links to all 4 channels on the Spreaker App...Dogman Tales... https://www.spreaker.com/podcast/dogman-tales--6640134My Bigfoot Sighting... https://spreaker.page.link/xT7zh6zWsnCDaoVa7 Bigfoot Eyewitness Radio... https://spreaker.page.link/WbtSccQm92TKBskT8 My Paranormal Experience https://www.spreaker.com/show/my-paranormal-experience Thanks for listening!

horror bear monster terror scary monsters nightmare scared creatures werewolf sasquatch spreaker cryptids werewolves comif dogman frightening terrifying booger dogmen lucan nightmarish lycans dogman encounters spreaker app myshopify dogman encounters show store

Archive 169 Bigfoot and Other Strange Creatures

ghosts story storytelling horror ufos vampires bigfoot paranormal audiobooks archive werewolf yeti sasquatch cryptids dogman buckner strange creatures lycanthrope

Play Episode Listen Later Jun 11, 2025 29:56

Archive 169 Bigfoot and Other Strange CreaturesJoin my Supporters Club for $4.99 per month for exclusive stories:https://www.spreaker.com/podcast/what-if-it-s-true-podcast--5445587/support

Bride of Monster Kid Radio #029 - Frankenstein's Bloody Terror with Beth and Derek

Monster Kid Radio

Play Episode Listen Later Jun 10, 2025 85:34

Full Moon June continues when Derek and Beth take on Paul Naschy's first turn as a lycanthrope in the movie Frankenstein's Bloody Terror (dir. Enrique Lopez Eguiluz). Plus the Classic Five with BadShark Blackhand, Kenny's Look at Famous Monsters of Filmland, and Mark Matzke's Beta Capsule Review (Ultraman Ace)! Voicemail: (360) 524-2484‬ Email: Phoenix Fan Fusion - Monster Kid Radio's Discord Server - Monster Kid Radio on Reddit - Monster Kid Radio on Twitch! - Monster Kid Radio on YouTube - Follow Mark MatzkeSmall Town Monsters - Deth Designs - Classic Horror Film Board - Executive Producer: Bride of Monster Kid Radio is a Production. All original content of Bride of Monster Kid Radio is licensed under a . You can learn more about Team Deth, our other projects like Deth Merchant, Mail Order Zombie, Deth Writer, and more at . Please rate and review Monster Kid Radio wherever you download your favorite podcasts. Next week on Bride of Monster Kid Radio: STAY TUNED!

twitch terror production frankenstein bloody werewolf voicemail famous monsters filmland paul naschy monster kid radio mark matzke

Ex-Bride of Satan Speaks (Part 2): Pre-Adamic Trauma, Werewolf Bloodlines and Redemption - Discovering Truth with Dan Duval

Fringe Radio Network

Play Episode Listen Later Jun 10, 2025 69:15

Surviving Extreme Realities: Tonya's Journey of Healing and RedemptionIn this gripping episode of Discovering Truth with Dan Duval, guest Tonya returns to delve deeper into her harrowing experiences with Satanic ritual abuse, government-sponsored mind control, time travel projects, Masonic abuse, and more.Tonya shares intricate details of her recovered memories, including a traumatic time travel experience to the time of Christ and her complex healing journey from deep-rooted traumas. She also discusses the manipulation and triggers she faced from projects like Montauk and her exposure to the GATE program and shaping technologies.Bringing a powerful closure to her narrative, Tonya shares profound moments of divine intervention and redemption, highlighting the unwavering presence and love of Jesus in her life.This extensive conversation not only dissects the dark depths of abuse but also shines a light on incredible moments of spiritual healing and hope.

Bigfoot Brawl - A Fight For Alpha Status

land sea mask frankenstein exorcist werewolf ballerina dark tower vision quests red death clayface monster high war between geek show

Play Episode Listen Later Jun 9, 2025 18:09

Bigfoot Brawl - A Fight For Alpha StatusAn 89-year-old veterinarian recounts a lifelong secret of his encounters with a Sasquatch family, beginning with his mother's sighting of a large, hairy creature during his birth. As a child on a farm in the deep South, he befriended a young Sasquatch he named Buddy, and they played together in his backyard until his deaf mother's terrified reaction to seeing Buddy and his mother led to a fence being built, ending their visits. Decades later, after returning to his hometown as a veterinarian, he reunited with an adult Buddy, who took him to a Sasquatch colony to assist with a difficult birth. There, he witnessed Buddy defeat the Alpha male to protect his mate and newborn, becoming the new leader. Over time, the man maintained a bond with the Sasquatch, even introducing his wife and children to them, fostering a unique connection between their families, which he now shares as he nears the end of his life, hoping for a reunion with Buddy and his loved ones in the afterlife.Join my Supporters Club for $4.99 per month for exclusive stories:https://www.spreaker.com/podcast/what-if-it-s-true-podcast--5445587/support

ghosts story south storytelling horror ufos vampires status alpha bigfoot paranormal buddy decades audiobooks werewolf yeti brawl sasquatch cryptids dogman buckner lycanthrope

Geekshow Live: I am always the werewolf

Geekshow Podcast

Play Episode Listen Later Jun 9, 2025 80:28

Frankenstein, Wednesday, M3GAN 2.0, Alien:Earth, Black Phone, Gen V, War Between the Land and Sea, Vision Quest, Monster High, Mask of the Red Death,Carrie, Clayface, Dark Tower, Exorcist, Star Wars: Starfighter, Sandman S2, Galactus Head, Rebecca reviews Ballerina and Life of Chuck, lots more

A Booger Bear Is Out There! - Dogman Encounters Episode 585